易明医药(002826) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 was ¥206,056,228.21, representing a 14.86% increase compared to the same period last year[4] - Net profit attributable to shareholders for Q3 2022 was ¥9,271,623.79, a 33.30% increase year-over-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥8,074,465.58, up by 9.48% from the previous year[4] - The basic earnings per share for Q3 2022 was ¥0.05, a 25.00% increase compared to the same period last year[4] - Operating revenue for the first nine months of 2022 reached CNY 591.77 million, an increase of 14.21% compared to CNY 518.14 million in the same period of 2021[9] - Total operating revenue for Q3 2022 reached CNY 591,767,346.30, an increase of 14.2% compared to CNY 518,143,668.07 in Q3 2021[24] - Net profit for Q3 2022 was CNY 21,481,158.04, representing a 24.5% increase from CNY 17,172,369.51 in the same period last year[25] - Earnings per share (EPS) for Q3 2022 was CNY 0.11, compared to CNY 0.09 in Q3 2021, indicating a growth of 22.2%[26] Assets and Liabilities - The total assets at the end of Q3 2022 reached ¥922,221,097.15, reflecting an 11.86% increase from the end of the previous year[4] - Total assets increased to CNY 922,221,097.15 from CNY 824,473,281.11, marking a rise of 11.8%[22] - Total liabilities rose to CNY 199,200,460.17, up from CNY 104,362,512.05, which is an increase of 90.8%[22] - The total equity attributable to shareholders at the end of Q3 2022 was ¥720,063,895.43, a slight increase of 0.37% from the previous year[4] - The total equity attributable to shareholders increased to CNY 720,063,895.43 from CNY 717,389,579.34, reflecting a slight growth of 0.4%[22] Cash Flow - The cash flow from operating activities for the year-to-date period was ¥91,887,610.24, a 32.69% increase compared to the same period last year[4] - Net cash flow from operating activities increased by 32.69% to CNY 91.89 million, up from CNY 69.25 million year-on-year[10] - Operating cash flow for the current period was ¥91,887,610.24, an increase of 32.9% compared to ¥69,249,556.94 in the previous period[27] - Total cash inflow from operating activities was ¥721,398,791.01, down 25.3% from ¥965,164,381.49 in the previous period[27] - Cash outflow from operating activities totaled ¥629,511,180.77, a decrease of 29.7% compared to ¥895,914,824.55 in the previous period[27] - Cash received from investment recovery was ¥100,000,000.00, down from ¥210,000,000.00 in the previous period[29] - The ending cash and cash equivalents balance increased to ¥200,638,206.96 from ¥140,234,893.13 in the previous period[29] Accounts Management - The company reported a significant increase in accounts receivable, which rose by 140.92% to ¥88,232,258.49 compared to the end of 2021[8] - Accounts payable surged by 313.53% to CNY 64.81 million, up from CNY 15.67 million, driven by business growth and accrued promotional service fees[10] - Other receivables decreased by 64.63% to CNY 32.95 million, down from CNY 93.17 million, primarily due to changes in sales management and settlement methods[9] - Contract liabilities decreased by 84.44%, indicating a reduction in advance payments received compared to the previous year[10] Expenses and Investments - Research and development expenses decreased by 51.75% to CNY 3.34 million, down from CNY 6.93 million, due to the completion of a previous project[10] - The company reported a net cash outflow from investing activities of CNY 101.40 million, an increase of 83.67% compared to the previous year[10] - The company has committed to a total of ¥10,000,000 in wealth management products, all of which are backed by its own funds[16] - The company has invested in structured deposits with a reference annualized yield of 3.3%[16] Shareholder Information - The total number of common shareholders at the end of the reporting period is 16,709[13] - The largest shareholder, Gao Fan, holds 26.40% of the shares, amounting to 50,335,682 shares, with 19,716,000 shares pledged[13] - The top ten shareholders do not have any disclosed relationships or agreements regarding concerted actions[13] Tax and Other Income - Income tax expenses increased by 47.22% to CNY 7.43 million, up from CNY 5.04 million, corresponding to profit growth[10] - Other comprehensive income increased by 148.53% to CNY 31.65 million, compared to a loss of CNY 65.23 million in the previous year[9] Audit Information - The company did not conduct an audit for the third quarter report[30]